CLINICAL_TRIALS
trial_result
· 2025-10-20
Clinical Trial Update: PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
Summary
A post-marketing surveillance trial evaluating intravenous spesolimab in patients with Generalized Pustular Psoriasis experiencing acute symptoms has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Generalized Pustular Psoriasis | Status: COMPLETED